Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Still a Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped up prior to trading on Wednesday . The stock had previously closed at $15.22, but opened at $16.30. Ono Pharmaceutical shares last traded at $16.30, with a volume of 300 shares trading hands.

Ono Pharmaceutical Price Performance

The company has a 50 day moving average of $13.91 and a 200 day moving average of $12.38. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10. The firm has a market cap of $7.66 billion, a price-to-earnings ratio of 18.31 and a beta of 0.25.

Ono Pharmaceutical (OTCMKTS:OPHLF) last posted its earnings results on Monday, February 2nd. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11. The firm had revenue of $892.70 million during the quarter, compared to analysts’ expectations of $727.58 million. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.